Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
KNSA Stock Chart & Stats
$46.02
$0.18(0.88%)
At close: 4:00 PM EST
$46.02
$0.18(0.88%)
Day’s Range― - ―
52-Week Range$18.26 - $49.12
Previous CloseN/A
Volume84.12K
Average Volume (3M)604.86K
Market Cap
$3.52B
Enterprise Value$3.27B
Total Cash (Recent Filing)$414.07M
Total Debt (Recent Filing)$9.50M
Price to Earnings (P/E)51.9
Beta0.55
Next Earnings
May 05, 2026EPS Estimate
0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding45,900,640
10 Day Avg. Volume755,693
30 Day Avg. Volume604,858
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)5.39
Price to Sales (P/S)4.52
P/FCF Ratio120.45
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue4.82
Enterprise Value/Gross Profit8.83
Enterprise Value/Ebitda38.28
Forecast
1Y Price Target
$55.60Price Target Upside20.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.36
Revenue Forecast (FY)$916.57M
Bulls Say, Bears Say
Bulls Say
Clinical Trial CatalystAnalyst highlights that derisked mid-to-late-stage data for KPL-387 could serve as a meaningful clinical catalyst by validating a less frequent dosing approach and strengthening clinical differentiation from existing therapy.
Commercial MomentumArcalyst's sustained sales growth and rising share of repeat prescribers indicate deeper market penetration and substantial room to expand treatment adoption among eligible patients.
Product Differentiation And ProfitabilityKPL-387's potential for fewer injections compared with the marketed therapy could improve patient adherence and, if approved, support higher margins due to full product ownership.
Bears Say
Competitive UncertaintyUncertainty around timelines for an oral inhibitor targeting the inflammasome after a corporate acquisition raises competitive risk that could alter market dynamics and pressure pricing or share for targeted pericarditis therapies.
Payer And Access PressureAnalyst warns that changes in payer plans and copay resets may create headwinds for revenue by reducing patient access or increasing out-of-pocket costs, constraining growth.
Regulatory And Clinical RiskApproval and commercial launch of KPL-387 depend on successful clinical trial outcomes and regulatory review, so trial setbacks or regulatory delays could postpone expected revenue contribution and limit near-term upside.
Kiniksa Pharmaceuticals News
KNSA FAQ
What was Kiniksa Pharmaceuticals’s price range in the past 12 months?
Kiniksa Pharmaceuticals lowest stock price was $18.25 and its highest was $49.12 in the past 12 months.
What is Kiniksa Pharmaceuticals’s market cap?
Kiniksa Pharmaceuticals’s market cap is $3.52B.
When is Kiniksa Pharmaceuticals’s upcoming earnings report date?
Kiniksa Pharmaceuticals’s upcoming earnings report date is May 05, 2026 which is in 59 days.
How were Kiniksa Pharmaceuticals’s earnings last quarter?
Kiniksa Pharmaceuticals released its earnings results on Feb 24, 2026. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.345 by -$0.175.
Is Kiniksa Pharmaceuticals overvalued?
According to Wall Street analysts Kiniksa Pharmaceuticals’s price is currently Undervalued.
Does Kiniksa Pharmaceuticals pay dividends?
Kiniksa Pharmaceuticals does not currently pay dividends.
What is Kiniksa Pharmaceuticals’s EPS estimate?
Kiniksa Pharmaceuticals’s EPS estimate is 0.24.
How many shares outstanding does Kiniksa Pharmaceuticals have?
Kiniksa Pharmaceuticals has 45,900,640 shares outstanding.
What happened to Kiniksa Pharmaceuticals’s price movement after its last earnings report?
Kiniksa Pharmaceuticals reported an EPS of $0.17 in its last earnings report, missing expectations of $0.345. Following the earnings report the stock price went down -8.208%.
Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals?
Currently, no hedge funds are holding shares in KNSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kiniksa Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.60 (20.82% Upside)
$55.60 (20.82% Upside)
Blogger Sentiment
Bullish
KNSA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 482.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 8.9%
Last 30 Days ▼ 8.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
115.14%
12-Months-Change
Fundamentals
Return on Equity
11.73%
Trailing 12-Months
Asset Growth
31.54%
Trailing 12-Months
Company Description
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
KNSA Company Deck
KNSA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and financial momentum driven by ARCALYST, with robust revenue growth (+65% Q4, +62% full year), rapidly expanding collaboration profit (+83% Q4, +96% full year), restored profitability, and meaningful cash generation. Management reiterated confident 2026 guidance ($900–$920M) and highlighted advancing pipeline programs (KPL-387 data expected H2 2026, KPL-1161 clinic entry by year-end). Offsetting items include rising operating expenses, seasonal Q1 headwinds, reliance on ARCALYST concentration, and uncertainty on peak market penetration and future product mix. Overall, positives materially outweigh the negatives, reflecting a constructive outlook contingent on continued execution.View all KNSA earnings summariesKNSA Stock 12 Month Forecast
Average Price Target
$55.60
▲(20.82% Upside)
Technical Analysis
Beam Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Centessa Pharmaceuticals
―
CG Oncology, Inc.
―
Ownership Overview
7.24% Insiders
15.51% Mutual Funds
14.50% Other Institutional Investors
52.05% Public Companies and
Individual Investors